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1. INTRODUCTION
The 3rd Annual Ontario Thoracic Cancer Conference
was held March 28–30, 2008, in Niagara-on-the-Lake,
bringing together those in community and academic
practice throughout the province who have an inter-
est in thoracic oncology. More than 150 attendees
participated this year, twice as many as participated
at the inaugural meeting. For the first time, abstracts
from trainees were submitted, and those abstracts
are published here. The selected highlights that fol-
low underscore the breadth of the work ongoing in
Ontario to combat the challenge of lung and other
thoracic cancers.
2. HIGHLIGHTS
2.1 Technological Innovations in Radiation Medicine
The first day’s keynote speaker, Dr. David Jaffray [Prin-
cess Margaret Hospital (PMH)], has been at the fore-
front of developments in cone-beam computed
tomography (CBCT) that have enabled a new era in im-
age-guided radiation therapy (IGRT) 1,2. Devices for
CBCT are now mounted on linear accelerators used for
radiation therapy and provide three-dimensional volu-
metric imaging that permits greater accuracy and pre-
cision in identifying tumour position and in delivering
treatment. Cone-beam computed tomography may also
allow for an assessment of the treatment response of
peripheral lung tumours, an important step in the de-
velopment of adaptive radiation therapy that seeks to
modify aspects of treatment according to response—
for example, to increase the likelihood of response or
to reduce normal-tissue toxicity 3.
Dr. Jaffray presented an overview of advances in
radiation therapy for lung tumours. He discussed methods
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for overcoming the uncertainty in tumour location as-
sociated with respiratory motion during treatment, and
he articulated the importance of taking this motion into
account during the treatment planning process. Ac-
counting for motion is now commonly achieved with
the use of “four-dimensional” computed tomography
(4DCT) imaging, a process that sorts CT images into
“bins” that correspond to various phases of the respi-
ratory cycle. By combining images from the various
phases (for example, inhale and exhale), tumour ex-
cursion can be approximated and included in the treat-
ment volume. Currently, 4DCT and CBCT are both
playing an important role in radioablative stereotactic
lung radiation therapy, an emerging treatment option
for certain lung tumours 4.
2.2 Evaluation of the Mediastinum in Lung Cancer
Accurate evaluation of nodal involvement in the medi-
astinum is a critical issue in thoracic oncology. Drs.
Lisa Ehrlich (Sunnybrook Health Sciences Centre),
Kam Soghrati [The Scarborough Hospital (TSH)], and
Abdollah Behzadi (TSH) addressed the multimodal
evaluation of the mediastinum. They covered the role
of positron-emission tomography (PET)–CT imaging,
the emerging option of endobronchial ultrasound (EBUS)
fine-needle aspiration cytology (FNAC), and mediasti-
noscopy 5. They noted that mediastinoscopy, like EBUS,
can be performed as a day-case procedure, and that it
may also offer additional information to the surgeon
about potential eligibility for trimodality therapy in cases
of suspected mediastinal involvement. Mediastinos-
copy has resolutely remained the “gold standard” de-
spite a number of innovations in mediastinal
assessment, but for how much longer that leading po-
sition will be maintained remains to be seen. Currently,
several centres in Ontario are either offering or con-
sidering EBUS. As with mediastinoscopy, EBUS is sub-
ject to operator dependency, and it further requires close
cooperation with the cytopathology team to realize its
potential. When EBUS is combined with endoscopic3RD ANNUAL ONTARIO THORACIC CANCER CONFERENCE
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ultrasound (EUS) FNAC, a more complete mediasti-
nal assessment is possible, and EUS FNAC can also
assess some potential sites of metastatic disease as
well 6. As with any sampling technique, the potential
for false negative results with FNAC should be borne
in mind. Attendees heard how individual centers are
taking steps to satisfy themselves that, in their hands,
EBUS can deliver results comparable to those with
mediastinoscopy.
The indications for 18Fluorodeoxyglucose (FDG)
PET–CT imaging are increasing 7. Currently, this
imaging modality can be accessed in the province of
Ontario through a combination of specified indications
(PET registry studies), case-by-case application (through
the PET Access Program), and clinical trials.
Noninvasive PET is useful in evaluating the mediasti-
num, but there are potential pitfalls. Causes of false
positive and false negative PET scans were reviewed,
and attendees were reminded that, in certain circum-
stances—for example when the primary lung cancer
has low FDG uptake—further investigation of a PET-
negative mediastinum should be considered 8. As tech-
nologies develop and patient access to them increases,
it seems likely that mediastinal assessment in thoracic
cancers will be achieved through a combination of
noninvasive and invasive approaches.
2.3 Setting Thoracic Surgical Standards in the
Province of Ontario
In a session that generated much discussion, the chal-
lenge of redesigning provincial thoracic surgery serv-
ices was tackled by Drs. Sudir Sundaresan (The Ottawa
General Hospital) and A. John Dickie (Peterborough
Regional Health Centre). They reviewed the setting of
thoracic surgery standards by Cancer Care Ontario
(CCO) to distinguish level I from level II surgical centers
9,10 and highlighted the many stakeholders in such a
large-scale service redesign. The issue promises to be
an emotive one, but there was broad support at the
meeting for the setting of thoracic surgical standards
so as to benefit patients and ultimately improve out-
comes. The stakeholders range from local communi-
ties, some of which are geographically quite isolated
and currently receive care from a community thoracic
surgeon, to hospitals that gain both tangibly and intan-
gibly from having a thoracic surgery service, to sur-
geons themselves.
The CCO standards were developed in response to
the question “What is the optimum organization for
the delivery of cancer-related thoracic surgery in On-
tario,” but as was pointed out, oncology is only one
part of the thoracic surgeon’s practice. The potential
effects of a service redesign of this kind on cancer and
non-cancer services alike will require close attention.
It was suggested during the discussion that, if signifi-
cant redesign is undertaken, careful planning and a
means of prospectively evaluating the effects should
be built into the process.
2.4 Lung Cancer Patterns of Care
Given his longstanding interest in cancer service de-
livery, patterns of care, and outcomes, Dr. William
Mackillop (Queen’s University) delivered a thought-
provoking and somewhat sobering review of variations
in the management and outcome of non-small-cell lung
cancer (NSCLC) in Ontario 11. Drawing on many years’
experience with the use of multisource population
databases, he reviewed the development of such tools
and described how they are being used. He presented
data demonstrating that, although the outlook for se-
lected patients may be improving, the overall outcome
of all patients with NSCLC has been little affected.
Whether more recent data incorporating the rise in
delivery of adjuvant chemotherapy for resected early-
stage lung cancer and other therapeutics will change
this finding remains to be seen 12. In pursuing max-
imization of outcomes for lung cancer patients on a
province-wide scale, it seems that regional variation
in therapy utilization and access to services needs to
be better understood and explicitly considered in health
care initiatives.
2.5 Contributions of the National Cancer Institute
of Canada Clinical Trials Group
Dr. Frances Shepherd (PMH), chair of the Lung Site of
the National Cancer Institute of Canada (NCIC) Clini-
cal Trials Group (CTG), described the significant im-
pact made by that group on the international stage.
Pivotal trials affecting lung cancer treatment were re-
viewed, including these studies:
￿ BR 6—In patients with limited-stage small-cell
lung cancer receiving chemotherapy and radiation,
early integration of thoracic radiation, as compared
with late or consolidative radiation, resulted in bet-
ter progression-free and overall survival 13.
￿ BR 10—In patients with completely resected,
early-stage NSCLC, adjuvant vinorelbine and
cisplatin, as compared with observation, prolonged
disease-free and overall survival 14.
￿ BR 21—In patients with advanced NSCLC who pro-
gressed after 1 or 2 lines of prior chemotherapy,
use of the epidermal growth factor receptor inhibi-
tor erlotinib, as compared with placebo, resulted
in better survival 15.
The NCIC CTG continues to play a major role in
national and international cooperative lung cancer stud-
ies. In doing so, it draws on an array of Canadian tal-
ent, including the expertise that exists within Ontario
in such areas as molecular medicine, therapeutics, and
quality-of-life and economic assessment.
Additional debate on the role of trimodality therapy
in selected patients with stage IIIA, non-bulky N2 disease
{Drs. Gail Darling (Toronto General Hospital) and Gordon
Okawara [Juravinski Cancer Centre (JCC)]} 16–19,DAHELE et al.
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discussion of the ethics of expensive cancer therapies
[Dr. Scott Berry (Odette Cancer Centre)] 20, and ex-
ploration of the role of the advanced practice nurse in
lung cancer [Ms. Lorraine Martelli–Reid (JCC)] 21 made
for a conference program that was both contemporary
and practical. It was rounded out by the presentation of
the top two scientific abstracts of the conference [Drs.
Jason Correia (McMaster University) and Gerald Lim
(PMH)], which were all subject to review by a panel
of judges.
3. SUMMARY
It is hoped that, in future years, the conference will
continue to grow and become an effective tool for fos-
tering multidisciplinary, multicentre collaboration and
for improving the outcome for lung cancer patients
throughout the province of Ontario.
Many thanks to all those who made this meeting
a success, including sponsors who provided unre-
stricted educational grants: Eli Lilly, Astra Zeneca,
and Sanofi–Aventis.
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Improving Outcomes for Early-Stage Non-Small-Cell
Lung Cancer with Stereotactic Body Radiation Therapy
M. Dahele, S. Pearson, T. Purdie, J.P. Bissonnette, A. Brade,
J.B.C. Cho, A. Sun, A. Hope, K. Franks, D.A. Jaffray, and A. Bezjak.
Radiation Medicine Program, Princess Margaret Hospital,
University Health Network, Toronto, ON; Department of Radiation
Oncology, University of Toronto, Toronto, ON; St. James Institute of
Oncology, The Leeds Teaching Hospitals NHS Trust, U.K.
Background and Objectives:  About 20% of patients have early-stage
non-small-cell lung cancer (NSCLC). Medically inoperable patients may re-
ceive radical radiation therapy (RT). Conventional RT outcomes are far inferior
to surgery. Delivered in only a few fractions, stereotactic body radiation
therapy (SBRT) gives ablative doses of RT that are expected to provide high
rates of local control.
Methods: Patients with medically inoperable T1-2N0M0 NSCLC are
treated on Research Ethics Board–approved SBRT protocols. Patients lie in
customized body moulds to minimize movement, and respiratory-synchro-
nized computed tomography (CT) scans for treatment planning identify tu-
mour position and motion. Multiple beams shape the radiation dose to the
target. Image guidance by CT before and during treatment verifies patient and
target position to 3 mm or less. Positron-emission tomography (PET) is used
for staging and response assessment.
Results:  In 76 patients (median age: 73 years) with 82 lesions (median
size: 2.3 cm), median follow-up is 8 months. In 49 patients (53 lesions),
follow-up is 6 months or more (median: 13 months). In the latter group, 2
lesions (4%) have failed locally, 11 patients (22%) have metastases (median:
9 months), and 9 patients (18%) have died (median: 11 months). Overall, the
3-month radiologic response rate is 56% (39 of 69 lesions). The most com-
mon acute (within 3-months) toxicities are grades 1 or 2 fatigue (41%), cough
(21%), skin erythema (14%), and chest wall pain (8%); late toxicities include
grades 1 or 2 chest wall pain (23%), grades 1 through 3 rib fracture (14%), and
grades 1 or 2 atelectasis (9%). Four grade 3 events have occurred (3 rib
fractures, 1 pneumonitis).
Conclusions: Treatment with SBRT is promising and well tolerated.
Local control is high. Long-term data will define efficacy. Clinical indications
are evolving; patients with oligometastatic NSCLC and pulmonary metastases
may benefit from SBRT.
Outcomes for Cervical Mediastinoscopy in a Community
Teaching Hospital
J. Lee, Y. Ung, A. Behzadi. Department of Surgery, The
Scarborough Hospital; Department of Radiation Oncology,
University of Toronto; and Odette Cancer Centre, Sunnybrook
Health Sciences Centre, Toronto, ON.
Background:   Cervical mediastinoscopy (CM) has been considered the
“gold standard” for pathology assessment of mediastinal abnormalities. In
view of the development of less invasive technologies for mediastinal evalu-
ation and their dissemination to community hospital settings, we sought to
determine the outcomes for CM in a community hospital by examining the
complication and false negative rates of this procedure as a benchmark for
future comparisons.
Methods:  We performed a retrospective chart review of 150 consecu-
tive patients who underwent CM between January 2004 and December 2006
(inclusive). Demographics of the patients and the complications and results of
the procedures performed were evaluated. In lung cancer patients who subse-
quently underwent thoracotomy, the false negative rate for CM was calculated.
Results: Median age of the patients was 69 years, and 52% were men.
Pathology included lung cancer (n = 105), metastatic disease (n = 6), lym-
phoma (n = 8), and benign diseases (n = 31). Postoperative complication rate
was 2.7%. No postoperative deaths occurred. Of 56 patients with negative
mediastinoscopy who underwent thoracotomy, 2 were later found to harbour
positive N2 nodes in lymph node stations accessible by CM, for a false
negative rate of 3.57%. Perioperative imaging of all false-positive CM cases
were negative for evidence of N2 involvement.
Conclusions: In this cohort of patients, CM was associated with no
mortalities and low rates of postoperative complications and false-negative
diagnostic imaging. The less-invasive endoscopic and radiologic technolo-
gies for mediastinal assessment should at least have the same false negative
rates and lower complication rates if they are to replace CM in the community
hospital setting.
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Video-Assisted Thoracoscopic Surgery Lobectomy for
Lung Cancer: Prospective Data on Initial Experience at a
Canadian Community Hospital
J.D. Correia, A.A. Walele, and A.S. Ashrafi. Department of
Surgery, McMaster University, Hamilton, ON, and Clinical
Teaching Unit, St. Catharines General Hospital, Niagara
Health System, ON.
Background and Objectives: Advantages of video-assisted thoraco-
scopic surgery (VATS) lobectomy, as compared with lobectomy by conven-
tional thoracotomy, include shorter hospital stay and reduced postoperative
pain. We examined the preliminary experience with VATS lobectomy in a
community hospital.
Methods: Data were prospectively collected on all patients that under-
went VATS lobectomy by a single surgeon at the St. Catharines General
Hospital between August 2006 and November 2007. All patients were dis-
charged on a standard narcotic protocol.
Results:  Lobectomy by VATS was performed in 28 patients [43% men;
median age: 67.5 years (range: 45–87 years)]. Preoperative percentage pre-
dicted forced expiratory volume in 1 s (FEV1) was median 82.0% (range: 54%–
120%) and percentage diffusion capacity (DLCO) was median 73.5% (range:
44%–111%).
Pathology revealed that 82.1% (n = 23) of patients had primary non-
small-cell lung cancer (NSCLC) stage IA (39.1%), stage IB (43.5%), stage IIA
(4.3%), stage IIB (8.7%), and stage IIIB (4.3%). Other pathology included
metastatic colorectal adenocarcinoma (n = 2), carcinoid (n = 1), hamartoma
(n = 1), and pseudotumour (n = 1). All patients had complete resection with
negative margins on pathology exam.
Two conversions to open thoracotomy for bleeding control occurred
(conversion rate: 7.1%). Median postoperative chest-tube days were 4 (range:
2–13 days). Length of hospital stay was median 5.5 days (range: 3–44 days).
No deaths were reported at 30-days of follow-up.
Discussion and Conclusions:   Lobectomy by VATS for lung cancer can
be performed safely in a community hospital with acceptable morbidity and
mortality. Lobectomy by VATS is a feasible alternative to conventional thora-
cotomy in the management of lung cancer.
The Long Journey of Lung Cancer Patients to Treatment
A. Sturdza, D. Payne, A. Sun, J.B.C. Cho, G. Kane, D. Hodgson,
J. Waldron, J. Catapano, F.A. Shepherd, S. Keshavjee, and
A. Bezjak. Princess Margaret Hospital, University Health
Network; and University of Toronto, Toronto, ON.
Background and Objectives: Treatment recommendations for lung
cancer patients require accurate staging and multidisciplinary assessment.
Our aim was to assess the delays to treatment decision-making in patients
referred to our institution for consideration of radical radiation.
Methods: Retrospective chart review of patients referred to the Princess
Margaret Hospital Lung Radiation Oncology Group with lung cancer from
January 1 to September 30, 2004, documented dates and findings related to
the critical steps leading to treatment decision.
Results: Among 284 patients referred with presumed non-metastatic
disease, the following intervals were documented: chest X-ray (CXR) to initial
computed tomography (CT) imaging, median 28 days; and CT imaging to
tissue biopsy, median 22 days. In 174 patients (61%), further imaging in our
institution to update old chest CT images or because of development of
symptoms was needed for completion of metastatic workup. Repeat CT chest
showed progression of the primary or lymph nodes in 85 patients (56%;
median 70 days from the initial CT), upstaging to incurable disease in 22
patients (13%), and no change in 32 patients (21%). A stage change occurred
in 33% of patients after completion of their workup, with most being up-
staged to stage IV. After completion of assessment, only 118 patients (41%)
were treated radically, at a median of 3.2 months from initial CXR.
Discussion and Conclusions: Our review documented extensive de-
lays at multiple steps, adding to more than 3 months from initial CXR to the
start of radiotherapy. These time delays were associated with progression of
cancer. Expediting multidisciplinary assessment of patients with suspected
lung cancer could result in improved outcomes.
Synergistic Antitumour Effects of Regulatory T-Cell
Blockade Combined with Pemetrexed in Murine
Malignant Mesothelioma
M. Anraku, Z. Yun, S. Keshavjee, L. Zhang, M.R. Johnston, and
M. de Perrot. Latner Thoracic Surgery Research Laboratories,
Toronto General Research Institute, University Health Network,
University of Toronto, ON.
Background/objectives: CD4+CD25+ regulatory T cells (“Tregs”)
can promote the growth of some tumours. We previously showed that the
presence of Tregs was associated with poor survival of patients with malig-
nant pleural mesothelioma). The objective of the present study was to
determine whether Treg blockade might enhance survival when combined
with pemetrexed in established tumours in our intrathoracic murine model
of malignant mesothelioma.
Materials and Methods: Murine malignant mesothelioma cells (AC29)
were injected into the right pleural cavity of CBA mice for tumour develop-
ment. Four days after the injection, tumour-bearing mice were treated with
pemetrexed with or without Treg blockade.
Results: The synergistic antitumour effect of Treg blockade and
pemetrexed on prolonged survival was associated with increased interleukin 2
and suppressed transforming growth factor β1 at the local tumour site. Signifi-
cantly decreased %Treg and increased %CD8+ cytotoxic T cells were observed
in mice treated with the combined protocol, but not in mice treated with
pemetrexed alone. The survival benefit was abrogated if anti-CD8 monoclonal
antibody was simultaneously administered.
Conclusions: Our findings suggest that Treg blockade combined with
pemetrexed can suppress mesothelioma growth in established tumour in vivo
by inducing greater antitumour immune reaction. This study also validates a
new intrathoracic tumour model of pleural effusion to explore the role of
antitumour immunity in murine malignant mesothelioma.
Prognostic Factors in Solitary Resected Brain Metastasis
from Non-Small-Cell Lung Cancer
A. Louie, G. Rodrigues, F. Whiston, and L. Stitt.
Department of Oncology, Division of Radiation Oncology,
London Regional Cancer Program; and Schulich School of
Medicine and Dentistry at the University of Western Ontario,
London, ON.
Background and Objectives: Reports in the medical literature have
described cases of extended survival of patients with stage IV non-small-cell
lung cancer (NSCLC) with solitary metastatic disease that have received aggres-
sive management both to the brain metastasis as well as to the local or
regional disease. The objective of the present research was therefore to analyze
prognostic factors that predict for outcome in this unique patient population.
Methods: We performed a single-institution retrospective chart review of
35 NSCLC patients with solitary brain metastasis treated with craniotomy and
whole-brain radiotherapy. Of these patients, 8 (22.9%) underwent chest surgery,
24 (68.6%) received chemotherapy, and 14 (40.0%) received thoracic radiation;
13 were otherwise stage I/II (37.1%), and 20 were stage III (57.1%). Mean age at
diagnosis was 58.5 years. Brain metastasis <3 cm was present in 18 (56.25%)
and >3 cm in 14 (43.75%).
Results: Median survival was 7.8 months. At last follow-up, 3 patients
(8.6%) were alive and well, 6 (17.1%) were alive with disease, 24 (68.6%)
had died of their disease, and 2 (5.7%) had died of other causes. Univariate
analysis demonstrated that lung surgery (p = 0.0033), primary lung treatment
more than 8 weeks after brain surgery (p = 0.0128), and stage I/II (p = 0.0467)
were predictive of overall survival.
Discussion and Conclusions: Survival remains poor for stage IV
NSCLC patients with a synchronous solitary brain metastasis. However, pa-
tients with thoracic disease amenable to local resection should be considered
for such therapy, because it may hold a survival advantage for them as
compared with patients with more locally-advanced disease.MEETING REPORT AND ABSTRACTS
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Hyperpolarized 3He Magnetic Resonance Imaging of
Radiation Pneumonitis: Initial Findings at 3.0 Tesla
L. Mathew, G. Rodrigues, and G. Parraga. Imaging Research Laborato-
ries, Robarts Research Institute; Department of Medical Biophysics;
Department of Oncology, The University of Western Ontario; Lawson
Health Research Institute; London Regional Cancer Program, London
Health Sciences Centre, London, ON.
Background and Objectives:  Hyperpolarized 3He magnetic resonance
imaging (HP 3He MRI) is a method of functional lung imaging allowing for
visualization of ventilation patterns and defects at a high resolution. In this
pilot study, we assessed potential 3He MRI phenotypes of radiation pneumoni-
tis in lung cancer patients post-radiation.
Methods:  Subjects were recruited from the London Regional Cancer
Program based on post-radiation clinical or radiologic evidence of pneumoni-
tis and spirometric measurement of forced expiratory volume in 1 s. We
scanned 4 subjects using HP 3He MRI imaging at 3.0 Tesla. Imaging occurred
during a 16-s breath-hold of HP 3He, using a spin-exchange optical pumping
system. The static ventilation images thus acquired enabled analysis of ven-
tilation patterns. A breath-hold-matched proton scan was also acquired to
allow for visualization of the thoracic cavity for anatomic comparison.
Results: Preliminary results in 4 subjects suggest that numerous changes
occur in the ventilation patterns of the lungs of subjects with pneumonitis
following radiation therapy. Ventilation defects were found distal to, and in
some cases coinciding with, treatment site and radiation pneumonitis location
in subjects with radiation pneumonitis resulting from lung cancer treatment.
Quantitative analysis of ventilation defect volume and direct comparison to X-
ray computed tomography results provide an explanation of the causes of
ventilation defects.
Conclusions and Discussion:  3He MRI is a valuable tool for the
visualization of regional damage resulting from pneumonitis post-radiation.
Analysis of radiation treatment parameters in conjunction with 3He MRI may
allow for improved understanding of lung response to radiation.
Effects of Genistein Following Fractionated Lung Irradiation
A.E. Para, V.L. Calveley, I.W.T. Yeung, J. Van Dyk, and R.P. Hill.
Departments of Medical Biophysics and of Radiation Oncology,
University of Toronto; Research Division, Ontario Cancer Institute/
Princess Margaret Hospital, and Radiation Medicine Program, Princess
Margaret Hospital, University Health Network, Toronto, ON; and
Radiation Treatment Program, London Regional Cancer Program,
London Health Sciences Centre; and Department of Oncology and
Medical Biophysics, University of Western Ontario, London, ON.
Introduction: We hypothesize that inflammatory cytokines and the
subsequent production of reactive oxygen species play a key role in radiation-
induced lung injury. Previously, we showed that genistein is effective in
preventing damage following single doses of radiation. The purpose of the
present study was to investigate protection by genistein with fractionated
doses of radiation.
Methods: C3H/HEJ mice were irradiated with a dose of 9 fractions of
3.1 Gy over 30 days (approximately 10 Gy single dose) after having been
maintained on a genistein diet (equivalent to approximately 10 mg/kg) just
before the first fraction. Damage was assessed over 28 weeks in cells obtained
from the lungs by a cytokinesis block micronucleus (MN) assay and by
monitoring changes in breathing rate and histology. Tumour protection was
also assessed by colony assay to determine cell survival following in situ
irradiation.
Results: Genistein was found to cause about a 50% reduction in the MN
damage observed during the fractionated treatment and to continue to reduce
MN formation at later times to background levels by 16 weeks. Genistein also
reduced collagen deposition by 30%. A slight protection against increases
in breathing rate were noted during weeks 11–18, but not at later times.
This protection did not increase overall survival. Using the KHT fibrosa-
rcoma model, we demonstrated no tumour protection by genistein follow-
ing single and fractionated radiation doses.
Conclusions: Our results suggest that genistein can protect lung cells
against damage caused by irradiation, but that such protection does not
extend to tumour cells growing in the lung.
An Institutional Review of the Current Medical Chart
Documentation Practices for Tobacco Use in Radiation
Oncology Patients with Lung or Head-and-Neck Cancer
L. Pan, J. Cohen, G. Okawara, and P. Nair. Juravinski Cancer Centre,
McMaster University, and Firestone Institute for Respiratory Health, St.
Joseph’s Hospital, Hamilton, ON; and University of Toronto and Ontario
Tobacco Research Unit, Toronto, ON.
Background: Smoking during radiation therapy increases the risk of
treatment failure and disease recurrence. In fact, complete response rates are
significantly lower in patients who continue to smoke during treatment.
Despite this, smoking cessation is seldom adequately addressed in tertiary
cancer centres.
Objectives: To retrospectively review medical chart documentation prac-
tices of radiation oncologists for tobacco use in patients with lung or head-and-
neck cancer seen in consultation at a tertiary care cancer centre.
Methods: The 134 charts examined for current radiation oncology
patients consisted of 67 consecutive charts in each of two tumour sites. Charts
were reviewed to determine the information documented by physicians on the
patients’ smoking status and any cessation counselling offered.
Results: Overall, information pertaining to smoking status was docu-
mented in 104 of 134 (77.6%) cases. Analysis by tumour type showed 79.1%
documentation of smoking status in lung cancer and 76.1% in head-and-neck
cancer. Smoking status information meeting a predetermined threshold level
of adequacy required in patient management was found in 67% of the charts
overall. History regarding second-hand smoke exposure was recorded in only
2% of charts. Lack of smoking status documentation occurred more frequently
in patients who had been previously seen by medical or surgical oncology
(30%) and in cases of treatment with palliative intent (30%). Documented
smoking cessation counselling by the oncologist occurred in 1 of 134 cases.
Conclusions and Discussion: With only 67% of patient charts in this
population containing adequate smoking status information, there appears to
be significant room for improvement. Adequate recording of tobacco use status
is instrumental as the first step in any effort to prompt cessation counselling in
subsequent follow-up visits. Our study emphasizes the need for more attention
to smoking cessation efforts in oncology patients.
Smoking Cessation in Radiation Oncology as the Missing
Drug in Clinical Trials—Identifying Patterns of Tobacco
Use and Barriers to Cessation in Oncology Patients
L. Pan, J. Cohen, P. Nair, G. Okawara. Juravinski Cancer Centre,
McMaster University, and Firestone Institute for Respiratory Health, St.
Joseph’s Hospital, Hamilton, ON; and University of Toronto and Ontario
Tobacco Research Unit, Toronto, ON.
Background: Abstinence from tobacco use, especially during treat-
ment, may significantly improve response rates to radiation therapy. The
magnitude of this improvement may be greater than that seen with drugs
such as radiosensitizers or chemotherapy. Nevertheless, some patients con-
tinue to smoke during radiation therapy.
Objectives: To perform a qualitative study to examine the tobacco use
behaviours and barriers to smoking cessation of patients diagnosed with lung
or head-and-neck cancer.
Methods: The study accrued 18 patients with a diagnosis of either lung
or head-and-neck cancer who were on active radiation therapy at a tertiary care
cancer centre. Detailed self-administered questionnaires or structured inter-
views (or both) were used to gather data regarding smoking behaviours,
barriers to cessation, and attitudes toward tobacco use cessation. Input was
also obtained from key health care providers.
Results: Smoking cessation represented a difficult achievement for most
patients, requiring multiple attempts. The most important reason for quitting
cited by former smokers was the patient’s cancer diagnosis. The most signifi-
cant patient-perceived barriers to smoking cessation included a belief of being
addicted to cigarettes, using cigarettes to “calm nerves,” cravings for a ciga-
rette, and fear of losing the enjoyment or pleasure derived from smoking.
Overall, patients’ perception that smoking is bad for one’s health increased
after their diagnosis of malignancy. For most patients, self-reported overall
quality of life improved or remained the same after quitting. Practitioner-based
barriers to tobacco-use cessation counselling primarily included a lack of time
in clinical consultation visits.
Conclusions and Discussion: Knowledge gained from this study is
instrumental for ongoing program development and may contribute to invest-
ment in resources for tobacco use cessation efforts in the oncology population.MEETING REPORT AND ABSTRACTS
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Toxicity of an Accelerated Hypofractionated Radiotherapy
Regimen for Early-Stage Non-Small-Cell Lung Cancer
H. Soliman, P. Cheung, I. Poon, J. Balogh, L. Barbera,
J. Spayne, C. Danjoux, M. Dahele, and Y. Ung. Odette Cancer
Centre, Sunnybrook Health Sciences Centre, Department of
Radiation Oncology, University of Toronto, Toronto, ON.
Background and Objectives: To retrospectively review the toxicity
profile of an accelerated hypofractionated radiotherapy alone for early-stage
non-small-cell lung cancer (NSCLC) in patients treated at a single institution.
Methods: A policy at our institution of treating early-stage NSCLC with-
out nodal involvement with an accelerated hypo-fractionated regimen of 4 Gy
daily was adopted in 1996. We report here the acute and late side effects
associated with that treatment.
Results: A total of 124 tumours were treated in 118 patients (56 men, 62
women). The median follow-up from end of treatment to last follow-up or
death was 23.2 months. The median age at diagnosis was 74.7 years. Almost
all patients (96.6%) were not candidates for surgery because of medical
comorbidities or old age. All patients were node-negative, with 75 T1 tu-
mours, 40 T2 tumours, and 9 T3/4 tumours. Most patients were treated with
48 Gy in 12 fractions (59.7%); the remainder were treated to 52 Gy in 13
fractions. The most common acute side effect was dermatitis (19.4%), fol-
lowed by cough (13.7%), dyspnea (6.5%), esophagitis (4.8%), and chest pain
(2.4%). Pneumonitis requiring steroids was reported in 5 patients, with 1
patient dying just 6 weeks after administration of steroids. Four rib fractures in
the treatment field were reported. Acute side effects were well tolerated with no
toxicity-related delay in completion of treatment.
Conclusions: Accelerated hypofractionated radiotherapy with this dose
fractionation is well tolerated in patients with early stage NSCLC who are
medically inoperable or refuse surgery.
Evaluation of Lung Tumour Regression with Four-
Dimensional Cone Beam Computed Tomography for
Adaptive Radiotherapy
G. Lim, A. Bezjak, J. Higgins, D. Moseley, D. Hope, A. Sun,
J. Cho, A. Brade, L. Le, and J.P. Bissonnette. Princess Margaret
Hospital, University Health Network, and University of Toronto,
Toronto, ON.
Background and Objectives: With the advent of on-treatment image
guidance technology such as cone-beam computed tomography (CT) scanning,
radiation oncologists are now better able to define the changing tumour target
over the 6- to 7-week course of radical lung cancer treatment. The objective of
our project was to use respiratory-correlated cone-beam CT (RCCBT) imaging to
study the volumetric, positional, and geometric changes that occur through-
out the course of radical radiotherapy in non-small-cell lung cancer (NSCLC) to
guide future research into adaptive radiotherapy for lung cancer patients.
Methods: Patients with pathology-confirmed NSCLC receiving radical
radiotherapy to a dose of 45 Gy or higher with concurrent chemotherapy were
included in the study. Serial cone-beam CT images were used to identify and
contour the tumour in the exhale phase of respiration on successive weeks after
the start of radiotherapy.
Results: We evaluated 13 consecutive lung patients for tumour regres-
sion. In 8 patients, RCCBCT images were of sufficient quality to assess tumour
regression. Tumour regression was identifiable in 5 of the 8 patients after 15
fractions and in 7 of the 8 patients after 20 fractions. We observed 19%–54%
tumour shrinkage after 20 fractions and 14%–71% tumour shrinkage at the end
of treatment.
Discussion and Conclusions: Current RCCBCT image quality allows
for assessment of tumours located more peripherally. In such cases, tumour
regression is documented in most patients. The feasibility of adaptive radio-
therapy in radical lung cancer treatment should be further investigated.